<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00991796</url>
  </required_header>
  <id_info>
    <org_study_id>CS1008-A-E202</org_study_id>
    <nct_id>NCT00991796</nct_id>
  </id_info>
  <brief_title>CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>Randomised, Double-Blinded, Placebo Controlled, Phase 2 Study of CS-1008 in Combination With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect on toxicity of the addition of CS 1008
      to a platinum based chemotherapy regimen on the progression-free survival (PFS) in subjects
      with stage IIIB wet or stage IV NSCLC.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in progression-free survival (PFS) of patients treated with CS-1008 and paclitaxel/carboplatin versus placebo and paclitaxel/carboplatin</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in overall survival of patients treated with CS-1008 and paclitaxel/carboplatin versus placebo and paclitaxel/carboplatin</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in objective response rate (ORR) of patients treated with CS-1008 and paclitaxel/carboplatin versus placebo and paclitaxel/carboplatin</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in duration of response of patients treated with CS-1008 and paclitaxel/carboplatin versus placebo and paclitaxel/carboplatin</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">109</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>CS-1008</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CS-1008 with carboplatin and paclitaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo with carboplatin and paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS-1008</intervention_name>
    <description>CS-1008 powder for concentrate for solution for infusion. six cycles of combination therapy with 3 weeks equal to one cycle. 10 mg/kg</description>
    <arm_group_label>CS-1008</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel concentrate for solution for infusion. once every 3 weeks for a maximum of 6 cycles. 175 mg/m2</description>
    <arm_group_label>CS-1008</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin concentrate for solution for infusion. once every 3 weeks for a maximum of 6 cycles. 6 mg/m2</description>
    <arm_group_label>CS-1008</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

          -  Measurable disease as defined by RECIST criteria

          -  Adequate organ and bone marrow function as evidenced by:

               -  Hemoglobin &gt;= 9 g/dL;

               -  ANC &gt;= 1.5 x 109/L;

               -  Platelet count &gt;= 100 x 109/L;

               -  Serum creatinine &lt; 1.5 mg/dL or creatinine clearance &gt; 60 mL/min;

               -  AST, ALT, and alkaline phosphatase &lt;= 2.5 x upper limit of normal (ULN) if
                  without liver metastasis and &lt;= 5.0 x ULN if liver metastasis;

               -  Total bilirubin &lt;= 2.0 x ULN.

          -  Men and women of childbearing potential must be willing to consent to using effective
             double barrier contraception (eg, hormonal contraceptives, bilateral tubal ligation,
             barrier with spermicidal, intrauterine device) while on treatment and for 3 months
             thereafter.

          -  All female subjects of childbearing potential must have a negative pregnancy test
             (serum or urine) result &lt;= 72 hours before initiating study treatment.

          -  Subjects must be fully informed about their illness and the investigational nature of
             the study protocol (including foreseeable risks and possible side effects) and must
             sign and date an IEC approved ICF before performance of any study specific procedures
             or tests.

        Exclusion Criteria:

          -  Anticipation of need for a major surgical procedure or radiotherapy (RT) during the
             study.

          -  Prior treatment with chemotherapy for their disease.

          -  History of any of the following conditions within 6 months before study enrolment:
             myocardial infarction; New York Heart Association (NYHA) class II or higher
             severe/unstable angina pectoris; coronary/peripheral artery bypass graft; NYHA class
             III or IV congestive heart failure; cerebrovascular accident or transient ischemic
             attack, pulmonary embolism, or other clinically significant thromboembolic event;
             clinically significant pulmonary disease (eg, severe chronic obstructive pulmonary
             disease or asthma); clinically significant pulmonary edema or anasarca.. See Section
             17.2 for NYHA Classification.

          -  Clinically significant pleural or pericardial effusions.

          -  Grade 2 or higher current peripheral neuropathy (See Section 17.3; NCI CTCAE, Version
             3.0).

          -  Clinically active brain metastasis (ie, untreated, still requiring therapy with
             steroids or RT, or with progression within 4 weeks after completion of RT); an
             uncontrolled seizure disorder; spinal cord compression; or carcinomatous meningitis.

          -  History of malignancy other than NSCLC, unless there is the expectation that the
             malignancy has been cured, and tumor specific treatment for the malignancy has not
             been administered within the previous 5 years.

          -  Clinically significant active infection that requires antibiotic therapy or Human
             Immunodeficiency Virus (HIV) positive subjects receiving antiretroviral therapy.

          -  Previous treatment with chemotherapy, CS 1008, other agonistic DR 5 or DR 4
             antibodies, or with TRAIL.

          -  Pregnant or breast feeding.

          -  Known history of hypersensitivity reactions to any of the components of CS 1008,
             carboplatin, or paclitaxel formulations.

          -  Serious intercurrent medical or psychiatric illnesses or any other conditions that in
             the opinion of the Investigator would impair the ability to give informed consent or
             unacceptably reduce protocol compliance or safety of the study treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asklepios Fachkliniken Munchen Gauting</name>
      <address>
        <city>Gauting</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum fur Pneumologie und Thoraxchirurgie</name>
      <address>
        <city>Grobhansdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2009</study_first_submitted>
  <study_first_submitted_qc>October 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2009</study_first_posted>
  <last_update_submitted>September 7, 2012</last_update_submitted>
  <last_update_submitted_qc>September 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

